ACT supports the production and distribution of a microbial restoration product that is saving lives and driving breakthrough research.

Alleviating Human Suffering

Our hope is to save lives through microbial restoration. Through our partnership with the University of Minnesota Microbiota Therapeutics Program, our encapsulated microbial restoration product has been used to treat over 140 people suffering from recurrent Clostridium difficile. In addition, over 450 patients have received colonoscopic Fecal Microbiota Transplants. With a greater than 90% success rate, this treatment is saving people's lives.

Driving a Research Frontier

ACT supports multidisciplinary, collaborative academic research focused on the human microbiome with one goal in mind...cures! Our research projects and interests span across many maladies including Crohn's Disease, Ulcerative Colitis, Diabetes, Clostridium difficile, Autism, Cancer, Allergies, Obesity, Depression, and more.

Microbial Restoration Product Development Publication Coming Soon!

80% success rate in Clostridium difficile (rCDI) patients given fecal microbiota transplant (FMT)

Clinicaltrial.gov identifier:

Fecal microbiota transplantation (FMT) is used to introduce healthy-people’s stool into the digestive tract of a patient suffering from recurrent Clostridium difficile infection (rCDI). “FMT involved transfer of fecal microorganisms from healthy donors to patients to correct antibiotic-induced dysbiosis, which is the primary casual risk factor for CDI in most patients”. Patients with C. difficile commonly have less gut bacterial diversity, so introducing different communities of bacteria is hypothesized to be beneficial for healing. 89 patients over time, were given 100 freeze-dried capsules with encapsulated donor material of FMT (cap-FMT). Patients were given oral antibiotic treatment (vancomycin), as typical treatment for C. difficile, until two days before taking the FMT capsules. The study concluded that 80% of the patients with recurrent Clostridium difficile infection benefitted from the fecal microbiota transplantation (FMT).

view trial

Antibiotics (anti-bacterials) have a negative impact on recovery after stomach surgery in mice.

Clinicaltrial.gov identifier:

The aim of this study was to see if antibiotic treatment before an invasive stomach surgery would have an effect on the recovery rates of mice. Researchers induced obesity in mice. Half of the mice were given vertical sleeve gastrectomy (VSG) surgeries where the stomach is reduced by half the size, and half of the mice were given sham surgeries (no part of the stomach was surgically removed). Before the surgeries, half of the mice were given antibiotics. It is known that antibiotics kill off certain gut bacterial communities. All the mice who were given antibiotics before their surgeries, had altered gut microbiomes, and detrimental outcomes. Metabolic changes were negative as the mice suffered longer recovery times after surgery, trouble regulating glucose levels after eating, and increased body fat. “Results of this study implicate the intestinal microbiota as an important contributor to metabolic homeostasis and a potentially modifiable target influencing clinical outcomes following the surgery.”

view trial

Human microbiota effectively transferred into mice models.

Clinicaltrial.gov identifier:

The purpose of this study was to find animal models that can be used for human microbiota studies. Unfortunately, using germ-free mice to run studies on the human gut microbiota is not possible today. A one-time transplant of the human microbial community into germ-free mice creates many medical changes. This means that germ-free mice need multiple steps for engraftment/transplant of the human microbial community, which will reduce the number of medical changes in the mice. This study, from the University of Minnesota Microbiota Therapeutics Program, found a new model of introducing the human gut microbiota into germ-free mouse models. By using sequential antibiotic therapies, engraftment of the human gut bacterial profile was successful in the mice. This is an important and positive step forward in the continuation of testing in animal models, thus translating into human gut microbiota research studies.

view trial

Encapsulated, freeze-dried microbes successfully engraft for Clostridium difficile patients

Clinicaltrial.gov identifier:

The purpose of this study was to see how a healthy persons’ stool would transplant into the digestive tract of Clostridium difficile (rCDI) patients via capsule. Each person’s microbiomes have different levels of each type of bacteria. Patients were given a capsule fecal microbiota transplant and measured outcomes were bacterial compositions in the patient’s stool after FMT. The study found that there are particular types of bacteria that will repopulate inside the digestive tract of a patient. Some types of bacteria will repopulate very quickly, some will need multiple FMT treatments, and some will not repopulate. The C. difficile patients who were cured by FMT were found to have drastic changes in gut bacterial composition; due to factors such as bile acid metabolism and bacterial community composition before the FMT.

view trial

Developed encapsulated microbiota product that is effectively treating Clostridium difficile

Clinicaltrial.gov identifier:

Fecal microbiota transplantation (FMT) was used in capsule form to treat Clostridium difficile (rCDI) patients. The FMT capsules were created through a freeze-drying procedure that preserved the donor’s gut bacteria at 100 billion cells per capsule. This procedure is revolutionary and is a new way to standardize FMT treatment in comparison to colonoscopy. Forty-nine rCDI patients were given different amounts of FMT capsules over time. 88% of the patients achieved clinical success without a reappearance of Clostridium difficile (rCDI). After one month of the FMT treatment, patients were found to have a “normalized” fecal microbiota community; meaning that the capsules repopulated the gut bacteria that was lacking in the patients’ microbiome. Even a single dose of healthy stool in capsule form was “highly successful in treating” patients suffering with Clostridium difficile who were not finding success through antibiotics.

view trial

Fecal microbiota transplant for pre-diabetic patients

Clinicaltrial.gov identifier:
NCT02730962

The purpose of this study is to determine whether changing the microbial composition in the colon can improve metabolism of sugar in people who are on the verge of developing diabetes (pre-diabetics). Study participants will undergo a fecal microbiota transplantation (FMT) using material from lean donors, as well as a series of tests prior to and after the transplant. The investigators will examine any changes in fecal bacterial composition associated with FMT and determine if any observed changes have an influence on blood sugar metabolism.

view trial

Partnered with World-Leading Researchers

ACT is partnered with the University of Minnesota Microbiota Therapeutics Program, a world leader in developing ways to repair damaged gut microbiota. Specifically, this group has developed methods to harvest intact, healthy microbiota from thoroughly screened stool donors and administer it to patients via colonoscopy or freeze-dried encapsulation. Their protocols have been adapted worldwide and have cured tens of thousands of patients suffering from intractable Clostridium difficile infections, a superbug formed from a complication of antibiotic treatments.

For questions on partnerships, please contact us at info@achievingcures.com.

University of Minnesota Microbiota Therapeutics Program

Sign up for our Newsletter

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form